Proteon Pharmaceuticals
Proteon Pharmaceuticals is a pioneer in bacteriophage technology, focusing on developing innovative solutions for global health challenges such as antimicrobial resistance, food safety, and animal health. The company harnesses the natural power of bacteriophages to create sustainable, targeted, and effective products for livestock farming, aquaculture, and related sectors. With a strong commitment to scientific research, regulatory compliance, and environmental sustainability, Proteon aims to transform farming practices and improve health outcomes worldwide.
Industries
Nr. of Employees
medium (51-250)
Proteon Pharmaceuticals
Ul. Tylna 3a, 90-364 Łódź, Poland
Patents
Products
BAFASAL
A bacteriophage-based zootechnical additive developed to reduce Salmonella Enteritidis contamination in poultry when administered via drinking water or liquid complementary feeds; subject to regulatory assessment in multiple jurisdictions.
BAFASAL PRO
A registered variant of a bacteriophage-based feed additive available in specific national markets for use in poultry production to help manage bacterial contamination and support production performance.
BAFASAL
A bacteriophage-based zootechnical additive developed to reduce Salmonella Enteritidis contamination in poultry when administered via drinking water or liquid complementary feeds; subject to regulatory assessment in multiple jurisdictions.
BAFASAL PRO
A registered variant of a bacteriophage-based feed additive available in specific national markets for use in poultry production to help manage bacterial contamination and support production performance.
Services
End-to-end phage development including isolation, sequencing, molecular characterization, automated screening, cocktail design and formulation for feed or water delivery; supported by omics, bioinformatics and AI workflows.
Joint R&D and field trials with aquaculture partners to identify prevalent pathogens, select phage candidates and evaluate efficacy in challenge trials and production settings.
Preparation of scientific dossiers, interaction with regulatory authorities and technical support through authorization pathways for zootechnical feed additives and similar products.
End-to-end phage development including isolation, sequencing, molecular characterization, automated screening, cocktail design and formulation for feed or water delivery; supported by omics, bioinformatics and AI workflows.
Joint R&D and field trials with aquaculture partners to identify prevalent pathogens, select phage candidates and evaluate efficacy in challenge trials and production settings.
Preparation of scientific dossiers, interaction with regulatory authorities and technical support through authorization pathways for zootechnical feed additives and similar products.
Expertise Areas
- Bacteriophage research and development for animal health
- Feed and water-based additive formulation for production animals
- Aquaculture and poultry challenge-trial design and execution
- Genomic and molecular characterization of bacteriophages
Key Technologies
- Phage isolation and propagation
- High-throughput screening automation
- Next-generation sequencing and genomic analysis
- Real-time PCR and molecular assays
News & Updates
Proteon Pharmaceuticals, a global leader in bacteriophage development for poultry farming, has become a member of the U.S. Poultry & Egg Association (USPOULTRY). The association promotes research, education, and sustainability in poultry industry, and Proteon will advocate for food safety and animal health through its bacteriophage solutions.
Proteon Pharmaceuticals has received over 2 million Euros to develop bacteriophage solutions to combat bacterial infections in aquaculture, aiming to reduce antibiotic use and improve fish health.
In 2016, Proteon Pharmaceuticals signed agreements for co-financing five research projects from the European Union for Euro 3.2 million, focusing on innovative products based on their phage-platform technology.
Proteon Pharmaceuticals signed an agreement with the Aqua-Spark fund, an international investment fund investing in sustainable aquaculture, to develop products that reduce antibiotic use in food production.
Proteon received funding to develop bacteriophage products for aquaculture, aiming to improve fish health and reduce antibiotic use.
Proteon received a significant EU grant to develop bacteriophage solutions for aquaculture, focusing on natural and effective treatments for fish health.
Proteon Pharmaceuticals, a global leader in bacteriophage development for poultry farming, has become a member of the U.S. Poultry & Egg Association (USPOULTRY). The association promotes research, education, and sustainability in poultry industry, and Proteon will advocate for food safety and animal health through its bacteriophage solutions.
Proteon Pharmaceuticals has received over 2 million Euros to develop bacteriophage solutions to combat bacterial infections in aquaculture, aiming to reduce antibiotic use and improve fish health.
In 2016, Proteon Pharmaceuticals signed agreements for co-financing five research projects from the European Union for Euro 3.2 million, focusing on innovative products based on their phage-platform technology.
Proteon Pharmaceuticals signed an agreement with the Aqua-Spark fund, an international investment fund investing in sustainable aquaculture, to develop products that reduce antibiotic use in food production.
Proteon received funding to develop bacteriophage products for aquaculture, aiming to improve fish health and reduce antibiotic use.
Proteon received a significant EU grant to develop bacteriophage solutions for aquaculture, focusing on natural and effective treatments for fish health.